BEBT-209

BEBT-209
  
  
Cyclin-dependent kinase (CDK) 4/6 inhibitors,including palbociclib, ribociclib, and abemaciclib, are novel agents that have shown promising results in the treatment of breast cancer.  Neutropenia was the most frequently reported adverse reaction with CDK4/CDK6 inhibitors.  CDK6 has a unique role in the hematopoietic system. CDK6 mainly expressed in hematopoietic cells. Loss of CDK6 in mice causes thymic atrophy and reduction in red blood cells, granulocytes, macrophages, neutrophils and platelets. BEBT-209 is a CDK4 selective inhibitor with reduced activities against CDK6. By reducing CDK6 inhibitory activities and increasing selective activities against CDK4, we believe BEBT-209 has the potential to possess significantly reduced toxicities against immunoeffector cells and other normal hematopoietic cells while retaining strong anti-cancer activities, thereby improving upon the currently available CDK4/6 inhibitors.